On October 13, 2025, Atossa Therapeutics announced the issuance of Israeli Patent No. 304863, titled "Methods for Making and Using Endoxifen." The patent covers enteric oral formulations containing at least 90% by weight Z‑endoxifen, optional impurity limits, defined release characteristics, dose strengths ranging from 1–4 mg to 8 mg, and pharmacokinetic performance targets such as steady‑state plasma levels.
The claims also protect a multi‑step crystallization process that enriches the Z‑isomer, ensuring consistent product quality and performance. The patent was granted on July 2, 2025, with priority to U.S. provisional applications filed in 2017–2018, and the company has received a certificate of renewal confirming fee payment and ongoing protection in Israel.
This new intellectual‑property milestone expands Atossa’s global protection for its lead program, reinforcing exclusivity in a major jurisdiction and mitigating the risk of generic competition. For a clinical‑stage company, securing robust IP is a critical step toward future commercialization and valuation, making the event material for investors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.